The role of whole-body MRI in pediatric oncology

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 5, 2014, Pages 342-352

  Atkin, Karen L ^a,c   Ditchfield, Michael R ^a,b  

^a SOUTHERN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

MRI; pediatric oncology; whole body

Indexed keywords

ARTICLE; ARTIFACT REDUCTION; BONE MARROW; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CHILDHOOD CANCER; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; HUMAN; IONIZING RADIATION; LANGERHANS CELL HISTIOCYTOSIS; LYMPHATIC MALFORMATION; LYMPHOMA; MOLECULAR IMAGING; NEUROBLASTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOMA; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; WHOLE BODY MRI;

CHILD; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; WHOLE BODY IMAGING;

EID: 84903766750     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000031     Document Type: Article

References (77)

1. Johnson KMR, Leavitt GD, Kayser HWM. Total body MR imaging in as little as 18 seconds. Radiology. 1997;202: 262-267.
2. Eustace S, Tello R, DeCarvalho V, et al. A comparison of whole-body TurboSTIR MR imaging and Planar 99mTc- Methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR. 1997; 169:1655-1661.
3. Dalrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR. 2001;177:229-236.
4. Mazumdar A, Siegel MJ, Narra V, et al. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. AJR. 2002;179:1261-1266.
5. Laffan EE, O'Connor R, Ryan SP, et al. Whole-body magnetic resonance imaging: a useful additional sequence in paediatric imaging. Pediatr Radiol. 2004;34:472-480.
6. Kellenberger CJ, Miller SF, Khan M, et al. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol. 2004;14:1829-1841.
7. Goo HW, Choi SH, Ghim T, et al. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol. 2005;35: 766-773.
8. Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006;36:1019-1031.
9. Kumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT. Pediatr Radiol. 2008;38:953-962.
10. Punwani S, Taylor SA, Bainbridge A, et al. Pediatric and adolescent lymphoma: comparison of whole-body STIR Half- Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology. 2010;25:182-190.
11. Punwani S, Taylor SA, Saad ZZ, et al. Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? Eur J Nucl Med Mol imaging. 2013;40: 373-385.
12. Siegel MJ, Acharyya S, Hoffer FA, et al. Whole-body MR imaging for staging of malignant tumors in pediatric patients: results of the American College of Radiology Imaging Network 6660 Trial. Radiology. 2013;266:599-609.
13. Kellenberger CJ, Epelman M, Miller SF, et al. Fast STIR whole-body MR imaging in children. Radiographics. 2004; 24:1317-1330.
14. Goo HW. Regional and whole-body imaging in pediatric oncology. Pediatr Radiol. 2011;41(suppl 1):S186-S194.
15. Krohmer S, Sorge I, Krausse A, et al. Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol. 2010;74:256-261.
16. Darge K, Jaramillo D, Siegel MJ. Whole-body MRI in children: current status and future applications. Eur J Radiol. 2008;68:289-298.
17. Chavhan GB, Babyn PS. Whole-Body MR imaging in children: principles, technique, current applications, and future directions. Radiographics. 2011;31:1737-1772.
18. Kwee TC, Takahara T, Vermoolen MA, et al. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol. 2010;40:1592-1602.
19. Dwyer AJ, Frank JA, Sank VJ, et al. Short-TI inversionrecovery pulse sequence: analysis and initial experience in cancer imaging. Radiology. 1988;168:827-836.
20. Disler DG, McCauley TR, Ratner LM, et al. Imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water. AJR. 1997;169:1439-1447.
21. Zajick DCJ, Morrison WB, Schweitzer ME, et al. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology. 2005;237:590-596.
22. Lauenstein TC, Semelka RC. Emerging techniques: wholebody screening and staging with MRI. J Magn Reson Imaging. 2006;24:489-498.
23. MacKenzie JD, Gonzalez L, Hernandez A, et al. Diffusionweighted and diffusion tensor imaging for pediatric musculoskeletal disorders. Pediatr Radiol. 2007;37:781-788.
24. Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR. 2007;188: 1622-1635.
25. Jaramillo D. Whole-body MR imaging, bone diffusion imaging: how and why? Pediatr Radiol. 2010;40:978-984.
26. Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic Applications of diffusion-weighted MRI in the body. J Magn Reson Imaging. 2012;35:257-279.
27. McDonald K, Sebire NJ, Anderson J, et al. Patterns of shift in ADC distributions in abdominal tumours during chemotherapy - feasibility study. Pediatr Radiol. 2011;41: 99-106.
28. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol. 2010;20:2027-2038.
29. Takahara T, Imai Y, Yamashita T. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing. STIR and high resolution 3D display. Radiat Med. 2004;22: 275-282.
30. Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18:1937-1952.
31. Humphries PD, Sebire NJ, Siegel MJ, et al. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology. 2007; 245:848-854.
32. Müller L-SO, Avenarius D, Olsen ØE. High signal in bone marrow at diffusion-weighted imaging with body background suppression (DWIBS) in healthy children. Pediatr Radiol. 2011;41:221-226.
33. Vasanawala SS, Jackson E. A method of rapid robust respiratory synchronization for MRI. Pediatr Radiol. 2010; 40:1690-1692.
34. Chavhan GB, Babyn PS, Jankharia BG, et al. Steady-state MR imaging sequences: physics, classification, and clinical applications. Radiographics. 2008;28:1147-1160.
35. Hirokawa Y, Isoda H, Maetani YS, et al. Artifact reduction and quality improvement in the upper abdomen with PROPELLER and Prospective Acquisition Correction (PACE) Technique. AJR. 2008;191:1154-1158.
36. Vertinsky AT, Rubesova E, Krasnokutsky MV, et al. Performance of PROPELLER relative to standard FSE T2-weighted imaging in pediatric brain MRI. Pediatr Radiol. 2009;39: 1038-1047.
37. MacKenzie JD, Vasanawala SS. State-of-the-art in pediatric body and musculoskeletal magnetic resonance imaging. Semin Ultrasound CT MR. 2010;31:86-99.
38. Foster K, Chapman S, Johnson K. MRI of the marrow in the paediatric skeleton. Clin Radiol. 2004;59:651-673.
39. Waitches G, Zawin JK, Poznanski AK. Sequence and rate of bone marrow conversion in the femora of children as seen on MR imaging: are accepted standards accurate? AJR Am J Roentgenol. 1994;162:1399-1406.
40. Murphy DT, Moynagh MR, Eustace SJ, et al. Bone marrow. Magn Reson Imaging Clin N Am. 2010;18:727-735.
41. Burdiles A, Babyn PS. Pediatric bone marrow MR imaging. Magn Reson Imaging Clin N Am. 2009;17:391-409.
42. Shabshin N, Schweitzer ME, Morrison WB, et al. High-signal T2 changes of the bone marrow of the foot and ankle in children: red marrow or traumatic changes? Pediatr Radiol. 2006;36:670-676.
43. Vande Berg BC, Malghem J, Lecouvet FE, et al. Magnetic resonance imaging of normal bone marrow. Eur Radiol. 1998;8:1327-1334.
44. Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study. Lancet. 2004;364: 2097-2105.
45. Brennan DD, Gleeson T, Coate LE, et al. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol. 2005;185:711-716.
46. Adams HJ, Kwee TC, VermoolenMA, et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDGPET. Eur Radiol. 2013;23:2271-2278.
47. Kwee TC, Takahara T, Luijten PR, et al. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol. 2010;75:215-220.
48. Holzapfel K, Duetsch S, Fauser C, et al. Value of diffusionweighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol. 2009; 72:381-387.
49. King AD, Ahuja AT, Yeung DK, et al. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology. 2007;245:806-813.
50. Kwee TC, Ludwig I, Uiterwaal CS, et al. ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. Magma (New York, NY). 2011;24:1-8.
51. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990;175:494-498.
52. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
53. Siegel MJ, Jaju A. MR imaging of neuroblastic masses. Magn Reson Imaging Clin N Am. 2008;16:499-513.
54. Lonergan GJ, Schwab CM, Suarez ES, et al. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002;22:911-934.
55. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298-303.
56. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289-297.
57. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243-257.
58. Nour-Eldin NE, Abdelmonem O, Tawfik AM, et al. Pediatric primary and metastatic neuroblastoma: MRI findings: pictorial review. Magn Reson Imaging. 2012;30:893-906.
59. Goo HW. Whole-body MRI of neuroblastoma. Eur J Radiol. 2010;75:306-314.
60. Kumar R, Shandal V, Shamim SA, et al. Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther. 2010;10:755-768.
61. Furth C, Amthauer H, Denecke T, et al. Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma. Pediatr Blood Cancer. 2006;47:607-611.
62. Biederer J, Hintze C, Fabel M. MRI of pulmonary nodules: technique and diagnostic value. Cancer Imaging. 2008;8: 125-130.
63. Schroeder T, Ruehm SG, Debatin JF, et al. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol. 2005;185:979-984.
64. Heye T, Ley S, Heussel CP, et al. Detection and size of pulmonary lesions: how accurate is MRI? A prospective comparison of CT and MRI. Acta Radiol (Stockholm, Sweden: 1987). 2012;53:153-160.
65. Phillips M, Allen C, Gerson P, et al. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52:97-101.
66. Binkovitz LA, Olshefski RS, Adler BH. Coincidence FDGPET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol. 2003;33:598-602.
67. Mueller WP, Melzer HI, Schmid I, et al. The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging. 2013;40:356-363.
68. Monsalve J, Kapur J, Malkin D, et al. Imaging of cancer predisposition syndromes in children. Radiographics. 2011; 31:263-280.
69. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12:559-567.
70. Cai W, Kassarjian A, Bredella MA, et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009;250:665-673.
71. Wunderbaldinger P, Paya K, Partik B, et al. CT and MR imaging of generalized cystic lymphangiomatosis in pediatric patients. AJR Am J Roentgenol. 2000;174:827-832.
72. Ley S, Ley-Zaporozhan J, Schenk J-P, et al. Whole-body MRI in the pediatric patient. Eur J Radiol. 2009;70:442-451.
73. Ohgiya Y, Hashimoto T, Gokan T, et al. Dynamic MRI for distinguishing high-flow from low-flow peripheral vascular malformations. AJR Am J Roentgenol. 2005;185:1131-1137.
74. Lidsky ME, Spritzer CE, Shortell CK. The role of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis and management of patients with vascular malformations. J Vasc Surg. 2012;56:757-764.
75. Hong TS, Greer M-LC, Grosse-Wortmann L, et al. Wholebody MR angiography: initial experience in imaging pediatric vasculopathy. Pediatr Radiol. 2011;41:769-778.
76. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380:499-505.
77. Kjaer A, Loft A, Law I, et al. PET/MRI in cancer patients: first experiences and vision from Copenhagen. Magma (New York, NY). 2013;26:37-47.